Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2019
Price : $35 *
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial skin diseases; Gram-positive infections; Skin infections
- Focus Adverse reactions
- Acronyms ABSSSI
- Sponsors Allergene
- 21 Jan 2019 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned End Date changed from 30 Sep 2018 to 31 Oct 2018.
- 10 Oct 2018 Planned primary completion date changed from 30 Sep 2018 to 31 Oct 2018.